177lu-dota0-tyr3-octreotate
Trade name: Dotatate
Small moleculeexperimentalImaging agent
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01578239)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-Lutetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 177lu-dota0-tyr3-octreotate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06398444 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2024 | Sinotau Pharmaceutical Group |
| NCT05894486 | Phase 2 | Jun 5, 2023 | Peking University |
| NCT05459844 | Phase 3 | Jul 31, 2022 | People's Liberation Army of China, Sinotau Pharmaceutical Group |
| NCT03923257 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2019 | Advanced Accelerator Applications, University of Iowa |
| NCT02705313 | N/A | Mar 7, 2016 | Advanced Accelerator Applications |
| NCT02230176 | Phase 2 | Feb 1, 2015 | Advanced Accelerator Applications, Institut Gustave Roussy, National Cancer Institute, France |
| NCT01578239 | Phase 3 | Sep 1, 2012 | Advanced Accelerator Applications, Pierrel Research |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanced Accelerator Applications | For profit | 4 | 2 | 3 | 2012 |
| Sinotau Pharmaceutical Group | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2015 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2022 |
| Pierrel Research | For profit | 1 | 0 | 1 | 2012 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2019 |
8 organizations
Page 1 / 1